Abiopharma

🔍 Sheena Jonathan (Executive)

Company: Natera, Inc. (NTRA)

Report Date: 2026-05-08

Detailed Transactions and Holdings:

• Sold 200 shares of Common Stock at $205.43 per share (Direct)
  Date: 2026-05-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 255,452.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 900 shares of Common Stock at $207.2411 per share (Direct)
  Date: 2026-05-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 254,552.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 700 shares of Common Stock at $208.1286 per share (Direct)
  Date: 2026-05-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 253,852.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 200 shares of Common Stock at $209.5725 per share (Direct)
  Date: 2026-05-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 253,652.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 1,150 shares of Common Stock at $210.345 per share (Direct)
  Date: 2026-05-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 252,502.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 85 shares of Common Stock at $199.5174 per share (Direct)
  Date: 2026-05-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 20,197.00 | transaction_form_type: 4 | Footnotes: F6, F7, F8
• Sold 345 shares of Common Stock at $201.1139 per share (Direct)
  Date: 2026-05-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 19,852.00 | transaction_form_type: 4 | Footnotes: F6, F9, F8
• Sold 290 shares of Common Stock at $202.5823 per share (Direct)
  Date: 2026-05-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 19,562.00 | transaction_form_type: 4 | Footnotes: F6, F10, F8
• Sold 30 shares of Common Stock at $202.84 per share (Direct)
  Date: 2026-05-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 19,532.00 | transaction_form_type: 4 | Footnotes: F6, F11, F8
• Sold 96 shares of Common Stock at $199.4346 per share (Direct)
  Date: 2026-05-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 20,186.00 | transaction_form_type: 4 | Footnotes: F6, F12, F8
• Sold 360 shares of Common Stock at $201.1923 per share (Direct)
  Date: 2026-05-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 19,826.00 | transaction_form_type: 4 | Footnotes: F6, F13, F8
• Sold 285 shares of Common Stock at $202.6829 per share (Direct)
  Date: 2026-05-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 19,541.00 | transaction_form_type: 4 | Footnotes: F6, F14, F8
• Sold 9 shares of Common Stock at $203.295 per share (Direct)
  Date: 2026-05-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 19,532.00 | transaction_form_type: 4 | Footnotes: F6, F8

Footnotes:

• F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
• F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.00 to $205.86 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.52 to $207.51 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.55 to $208.50 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.2250 to $209.9200 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.
• F7: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.00 to $199.8950 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F8: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
• F9: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.81 to $201.74 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F10: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.83 to $202.75 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F11: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.83 to $202.85 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F12: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.00 to $199.8950 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F13: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.81 to $201.75 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F14: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.9750 to $202.85 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.